FY2025 · ended Dec 31, 2025 · Revenue $33.48M, +1169.2% YoY · Filed Mar 12, 2026
Orchestra BioMed Holdings, Inc. (OBIO) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $33.5 million and a net loss of $52.7 million. Free cash flow was -$49.5 million. As of Jun 30, 2026 it held $117.1 million in cash and investments and $1.3 million in total debt.
Revenue (TTM)
$31.98M
+986.1% vs year-ago TTM
Net income (TTM)
$-59.03M
+15.3% vs year-ago TTM
Operating cash flow (TTM)
$-58.32M
+1.8% vs year-ago TTM
Free cash flow (TTM)
$-59.10M
+1.0% vs year-ago TTM
EPS (TTM)
$-0.99
+45.8% vs year-ago TTM
Dividend per share
None
Shares outstanding
58.52M
+52.7% vs prior year
Net cash
$115.73M
as of Jun 30, 2026
Operating margin
-181.4%
FY 2026
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- OBIO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New Hope, PA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1814114
- Former names
- Health Sciences Acquisitions Corp 2 (until Jan 26, 2023)
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $33.5M | $2.6M | $2.8M | — | — |
| Operating income | -$51.8M | -$64.3M | -$51.5M | -$32.7M | -$394,756 |
| Net income | -$52.7M | -$61.0M | -$49.1M | -$33.6M | -$378,753 |
| Diluted EPS | -$1.11 | -$1.66 | -$1.48 | -$2.24 | — |
| Operating cash flow | -$49.0M | -$50.6M | -$46.1M | -$29.3M | -$272,362 |
| Free cash flow | -$49.5M | -$50.8M | -$46.2M | — | — |
| Total assets | $114.9M | $76.2M | $95.2M | $95.6M | $161.8M |
| Total liabilities | $51.5M | $43.2M | $27.2M | $43.0M | $5.8M |
| Stockholders' equity | $53.6M | $33.0M | $68.0M | — | — |
| Cash and investments | $111.4M | $70.1M | $87.5M | $19.8M | $1.8M |
| Total debt | $16.7M | $17.2M | $1.7M | — | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Oct 1, 2026 | Oct 1, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 8, 2026 | Sep 8, 2026 |
| 10-Q | Quarterly report | Aug 10, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 23, 2026 | Jun 23, 2026 |
| 10-Q | Quarterly report | May 12, 2026 | Mar 31, 2026 |
| ARS | Annual report to shareholders | Apr 29, 2026 | Dec 31, 2025 |
All 412 Orchestra BioMed Holdings, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.